Revance Therapeutics, Inc. (RVNC) Financials
RVNC Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 478.5 million | 630.1 million |
2023-09-30 | 532.5 million | 638.7 million |
2023-06-30 | 597.5 million | 570.7 million |
2023-03-31 | 547.8 million | 574.5 million |
RVNC Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -44.5 million | 8.8 million |
2023-09-30 | -55.5 million | 10.3 million |
2023-06-30 | -53.1 million | 15.6 million |
2023-03-31 | -70.4 million | 13.1 million |
RVNC Net Income
No data available :(
RVNC Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 254.5 million | - | 49.3 million |
2023-09-30 | 300.2 million | - | 59.5 million |
2023-06-30 | 319.7 million | 380.3 million | 52.0 million |
2023-03-31 | 273.9 million | 379.9 million | 55.9 million |
RVNC Shares Outstanding
RVNC Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 1.8 million | 19.7 million | -169.1 million | 253.4 million |
2023-09-30 | 4.5 million | 13.1 million | 67.7 million | - |
2023-06-30 | 266000 | 22.8 million | 76.3 million | 1.0 million |
2023-03-31 | 870000 | 23.2 million | 63.9 million | 2.1 million |
RVNC Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 69.8 million | 18.9 million |
2023-09-30 | 56.8 million | 19.4 million |
2023-06-30 | 58.1 million | 21.3 million |
2023-03-31 | 49.3 million | 16.2 million |
RVNC
Price: $3.80
52 week price:
Earnings Per Share: -3.83 USD
P/E Ratio: -1.12
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 728800
Ebitda: -30.2 millionMarket Capitalization: 413.7 million